...
vstm-img

Verastem Inc, Common Stock

VSTM

NAQ

$4.26

-$0.34

(-7.39%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$204.73M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
790.50K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.14
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.1 L
$14.22 H
$4.26

About Verastem Inc, Common Stock

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameVSTMSectorS&P500
1-Week Return-13.24%-2.06%-0.55%
1-Month Return11.52%-1.92%2.72%
3-Month Return57.2%-10.4%7.66%
6-Month Return30.28%-4.6%10.15%
1-Year Return-45.45%4.06%27.53%
3-Year Return-84.43%1.94%32.31%
5-Year Return-70.42%36.48%89.2%
10-Year Return-95.89%97.46%194.59%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue17.46M88.52M2.05M2.60M-[{"date":"2019-12-31","value":19.72,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":2.32,"profit":true},{"date":"2022-12-31","value":2.93,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue2.81M33.74M206.00K118.00K62.00K[{"date":"2019-12-31","value":8.32,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":0.61,"profit":true},{"date":"2022-12-31","value":0.35,"profit":true},{"date":"2023-12-31","value":0.18,"profit":true}]
Gross Profit14.65M54.77M1.85M2.48M(62.00K)[{"date":"2019-12-31","value":26.75,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":3.37,"profit":true},{"date":"2022-12-31","value":4.52,"profit":true},{"date":"2023-12-31","value":-0.11,"profit":false}]
Gross Margin83.92%61.88%89.97%95.45%-[{"date":"2019-12-31","value":87.92,"profit":true},{"date":"2020-12-31","value":64.82,"profit":true},{"date":"2021-12-31","value":94.25,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses146.99M104.13M63.46M75.53M92.08M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":70.84,"profit":true},{"date":"2021-12-31","value":43.17,"profit":true},{"date":"2022-12-31","value":51.39,"profit":true},{"date":"2023-12-31","value":62.65,"profit":true}]
Operating Income(132.34M)(49.36M)(61.41M)(72.94M)(92.08M)[{"date":"2019-12-31","value":-13234100000,"profit":false},{"date":"2020-12-31","value":-4936000000,"profit":false},{"date":"2021-12-31","value":-6140900000,"profit":false},{"date":"2022-12-31","value":-7293700000,"profit":false},{"date":"2023-12-31","value":-9208400000,"profit":false}]
Total Non-Operating Income/Expense(33.09M)(33.45M)(19.58M)(1.80M)6.09M[{"date":"2019-12-31","value":-543.61,"profit":false},{"date":"2020-12-31","value":-549.46,"profit":false},{"date":"2021-12-31","value":-321.65,"profit":false},{"date":"2022-12-31","value":-29.52,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(149.21M)(67.53M)(71.20M)(73.81M)(87.37M)[{"date":"2019-12-31","value":-14920900000,"profit":false},{"date":"2020-12-31","value":-6753200000,"profit":false},{"date":"2021-12-31","value":-7120000000,"profit":false},{"date":"2022-12-31","value":-7381200000,"profit":false},{"date":"2023-12-31","value":-8736700000,"profit":false}]
Income Taxes19.97M194.00K9.90M36.00K(87.37M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":0.97,"profit":true},{"date":"2021-12-31","value":49.58,"profit":true},{"date":"2022-12-31","value":0.18,"profit":true},{"date":"2023-12-31","value":-437.56,"profit":false}]
Income After Taxes(169.18M)(67.73M)(81.10M)(73.85M)-[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(149.21M)(67.73M)(71.20M)(73.81M)(76.81M)[{"date":"2019-12-31","value":-14920900000,"profit":false},{"date":"2020-12-31","value":-6772600000,"profit":false},{"date":"2021-12-31","value":-7120000000,"profit":false},{"date":"2022-12-31","value":-7381200000,"profit":false},{"date":"2023-12-31","value":-7680700000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(169.18M)(67.73M)(81.10M)(73.85M)(87.37M)[{"date":"2019-12-31","value":-16917600000,"profit":false},{"date":"2020-12-31","value":-6772600000,"profit":false},{"date":"2021-12-31","value":-8110000000,"profit":false},{"date":"2022-12-31","value":-7384800000,"profit":false},{"date":"2023-12-31","value":-8736700000,"profit":false}]
EPS (Diluted)(2.01)(0.39)(0.41)(0.38)(3.22)[{"date":"2019-12-31","value":-201,"profit":false},{"date":"2020-12-31","value":-39,"profit":false},{"date":"2021-12-31","value":-41,"profit":false},{"date":"2022-12-31","value":-38,"profit":false},{"date":"2023-12-31","value":-322,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

VSTM
Cash Ratio 3.03
Current Ratio 3.23

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

VSTM
ROA (LTM) -47.31%
ROE (LTM) -136.87%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

VSTM
Debt Ratio Lower is generally better. Negative is bad. 0.75
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.09

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

VSTM
Trailing PE NM
Forward PE NM
P/S (TTM) 20.47
P/B 18.83
Price/FCF NM
EV/R 15.77
EV/Ebitda NM
PEG NM

FAQs

What is Verastem Inc share price today?

Verastem Inc (VSTM) share price today is $4.26

Can Indians buy Verastem Inc shares?

Yes, Indians can buy shares of Verastem Inc (VSTM) on Vested. To buy Verastem Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VSTM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Verastem Inc be purchased?

Yes, you can purchase fractional shares of Verastem Inc (VSTM) via the Vested app. You can start investing in Verastem Inc (VSTM) with a minimum investment of $1.

How to invest in Verastem Inc shares from India?

You can invest in shares of Verastem Inc (VSTM) via Vested in three simple steps:

  • Click on Sign Up or Invest in VSTM stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Verastem Inc shares
What is Verastem Inc 52-week high and low stock price?

The 52-week high price of Verastem Inc (VSTM) is $14.22. The 52-week low price of Verastem Inc (VSTM) is $2.1.

What is Verastem Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Verastem Inc (VSTM) is

What is Verastem Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Verastem Inc (VSTM) is 18.83

What is Verastem Inc dividend yield?

The dividend yield of Verastem Inc (VSTM) is 0.00%

What is the Market Cap of Verastem Inc?

The market capitalization of Verastem Inc (VSTM) is $204.73M

What is Verastem Inc’s stock symbol?

The stock symbol (or ticker) of Verastem Inc is VSTM

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top